SCHEMBL365671

SCHEMBL365671

COc1ccc(Cn2cc3c(n2)CC(OC(=O)N(C)C)CC(Br)C3=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.43
FFAR4 Q5NUL3 2/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
CACNA1G O43497 3/20 0.35
CACNA1H O95180 3/20 0.35
CACNA1I Q9P0X4 3/20 0.35
CHRM1 P11229 2/20 0.35
CHRM3 P20309 2/20 0.35
CHRM2 P08172 1/20 0.35
CYP2C19 P33261 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALDH1A1 P00352 2/20 0.34
HSD17B10 Q99714 1/20 0.34
MMP1 P03956 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365650 0.86 AADAT (0.46) AADATMEN1NPC1RAB9AKMT2A
SCHEMBL365560 0.83 AADAT (0.44) AADATFFAR4LMNAMAPK1CACNA1G
SCHEMBL7684049 0.81 AADAT (0.47) AADATSMN1; SMN2MEN1NPC1RAB9A
SCHEMBL29191591 0.75 AADAT (0.48) AADATFFAR4CACNA1GCACNA1HCACNA1I
SCHEMBL29191593 0.75 AADAT (0.48) AADATFFAR4CACNA1GCACNA1HCACNA1I
SCHEMBL365853 0.74 AADAT (0.45) AADATLMNAMAPK1SMN1; SMN2MEN1
SCHEMBL6837143 0.74 AADAT (0.45) AADATSMN1; SMN2MEN1KMT2ACYP3A4
SCHEMBL15182502 0.73 AADAT (0.43) AADATMEN1NPC1RAB9AKMT2A
SCHEMBL365849 0.73 AADAT (0.44) AADATMEN1NPC1RAB9AKMT2A
SCHEMBL365744 0.70 AADAT (0.47) AADATSMN1; SMN2MEN1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885FFAR4 67/4885LMNA 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.